logo

For the Inventor, By the Inventor

Lund, Sweden

Xintela Ab


USPTO Granted Patents = 15

% Expired Patents = 40.0



Trademarks = 2

Forward Citations = 24

Loading Chart...
Loading Chart...

12 inventors (with patents filed for the assignee):

goldMedal Evy Lundgren-Åkerlund (8 out of 10 patents)

silverMedal Evy Lundgren Åkerlund (4 out of 4 patents)

bronzeMedal Katarzyna Chmielarska Masoumi (3 out of 3 patents)

4.  Jan Talts (2 out of 6 patents)

5.  Ramiro Gisler (1 out of 1 patent)

6.  Evy Lundgren-Ãkerlund (1 out of 1 patent)

7.  Evy Lundgren-Äkerlund (1 out of 1 patent)

8.  Christina Uvebrant (1 out of 1 patent)

9.  Evy Lundgren Åkerlund (1 out of 1 patent)

10.  Moustafa Elmasry (1 out of 1 patent)

11.  Hooi Ching Lim (1 out of 1 patent)

12.  Ahmed Elserafy (1 out of 1 patent)

13.  Folke Sjöberg (1 out of 1 patent)

14.  Evy Lundgren Akerlund (0 patent)

15.  Evy Lundgren-Akerlund (0 patent)


15 patents:

1. 12599633 - Mesenchymal stem cells for use in the treatment of skin defects (2026-04-14),
2. 12247222 - Quality assurance of chondrocytes (2025-03-11),
3. 11725188 - Quality assurance of chondrocytes (2023-08-15),
4. 11517593 - Prevention and treatment of bone and cartilage damage or disease (2022-12-06),
5. 10994022 - Detection and treatment of malignant tumours in the CNS (2021-05-04),
6. 10781424 - Quality assurance of chondrocytes (2020-09-22),
7. 10087253 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2018-10-02),
8. 10081666 - Integrin heterodimer and a subunit thereof (2018-09-25),
9. 9365649 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2016-06-14),
10. 8895253 - Integrin heterodimer and a subunit thereof (2014-11-25),
11. 8563255 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2013-10-22),
12. 8105791 - Marker for stem cells and its use (2012-01-31),
13. 8048991 - Antibody to an integrin heterodimer and/or a subunit thereof (2011-11-01),
14. 8012696 - Monoclonal antibody capable of binding integrin alpha 10 beta 1 (2011-09-06),
15. 7749710 - Marker for stem cells and its use (2010-07-06),
Company Overview
Xintela Ab is a biotechnology company based in Lund, Sweden, specializing in the development of innovative therapies for regenerative medicine and cancer treatment. The company focuses on harnessing its proprietary technology platform, which is centered around the identification and characterization of specific stem cells and their applications in tissue repair and cancer immunotherapy. Xintela aims to advance healthcare solutions through its research in cell-based therapies, contributing to the evolving landscape of medical science.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

15 Patents

#31 in Lund

#432 in Sweden

#39,921 in the World

Lund, SE
Lund, Sweden

Xintela Ab

Forward Citations = 24

12 inventors:

goldMedal Evy Lundgren-Åkerlund (8 out of 10 patents)

silverMedal Evy Lundgren Åkerlund (4 out of 4 patents)

bronzeMedal Katarzyna Chmielarska Masoumi (3 out of 3 patents)

4.  Jan Talts (2 out of 6 patents)

5.  Ramiro Gisler (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Xintela Ab. Retrieved from https://idiyas.com/company/xintela-ab

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…